OVARIAN CANCER SCREENING STUDY

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 本研究旨在探讨CA125作为高危妇女早期卵巢癌筛查工具的有效性。这些妇女是根据家族和个人癌症病史以及BRCA1或BRCA2突变状态招募的。每三到六个月抽血一次，并测量CA125水平。每个CA125结果都用计算机算法进行评估，以生成发生卵巢癌的个人特定风险水平。被确定为风险较高的女性被提供经阴道超声检查来评估她们的卵巢。根据超声结果，妇女可以与妇科肿瘤医生会面，进行个性化的治疗。注册的有卵巢的女性最初每三个月接受一次跟踪，但后来改变了方案，每六个月对这些女性进行一次跟踪，直到研究结束。在研究过程中摘除卵巢的女性被要求参加最后一次随访，以比较当前的CA125水平与以前的水平。这些妇女签署了一份单独的表格，表明她们打算留在研究中并参与最后的后续行动。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study aims to determine the efficacy of CA 125 as a screening tool for detecting early stage ovarian cancer in women at high risk. Women have been recruited based on family and personal history of cancer and BRCA1 or BRCA2 mutation status. A blood draw is done and CA 125 levels are measured every three to six months. Each CA 125 result is evaluated with a computer algorithm to generate an individual specific risk level of developing ovarian cancer. Women determined to be at higher risk are offered trans-vaginal sonography to evaluate their ovaries. As warranted, based on the ultrasound results, women may meet with a gynecological oncologist for personalized management. Enrolled women who have ovaries were originally followed every three months, but the protocol has since changed and the women are being follow-up every six months until the end of the study. Women who have their ovaries removed during the course of the study are asked to participate in one final follow-up to compare a current CA 125 level with previous levels. A separate form is signed by these women to indicate their intent to remain in the study and participate in the final follow-up.